Micromem Technologies Launches Ultra-Sensitive Liquid-Phase Sensor Targeting Disease Biomarkers with Breakthrough Picomolar Detection
Micromem Technologies (OTCQB: MMTIF) has unveiled a groundbreaking liquid-phase nanowire bio-chemical sensor designed for ultra-sensitive disease biomarker detection. The sensor achieves 1 picomolar detection limits and 20mV/decade sensitivity, specifically targeting TREM-1, a crucial inflammatory marker.
The platform, developed from work for the Department of National Defence, utilizes standard photolithography for cost-effective manufacturing. Key features include pM-level detection, customizable biomarker targeting, real-time output, and integration capability with point-of-care devices. The technology addresses a projected $100 billion USD biomarker diagnostics market by 2030.
Micromem Technologies (OTCQB: MMTIF) ha presentato un innovativo sensore bio-chimico a nanofili in fase liquida progettato per il rilevamento ultrasensibile di biomarcatori patologici. Il sensore raggiunge un limite di rilevamento di 1 picomolare e una sensibilità di 20 mV/decade, mirata specificamente a TREM-1, un importante marcatore dell'infiammazione.
La piattaforma, sviluppata a partire da lavori per il Department of National Defence, sfrutta la fotolitografia standard per una produzione a basso costo. Le caratteristiche principali includono rilevamento a livelli pM, targeting personalizzabile dei biomarcatori, output in tempo reale e possibilità di integrazione con dispositivi point-of-care. La tecnologia si rivolge a un mercato della diagnostica dei biomarcatori stimato a 100 miliardi di dollari USA entro il 2030.
Micromem Technologies (OTCQB: MMTIF) ha dado a conocer un novedoso sensor bioquímico de nanohilos en fase líquida diseñado para la detección ultrasensible de biomarcadores de enfermedad. El sensor alcanza un límite de detección de 1 picomolar y una sensibilidad de 20 mV/decada, específicamente dirigido a TREM-1, un marcador inflamatorio clave.
La plataforma, desarrollada a partir de trabajos para el Department of National Defence, utiliza fotolitografía estándar para una fabricación rentable. Sus características principales incluyen detección a niveles pM, orientación de biomarcadores personalizable, salida en tiempo real y capacidad de integración con dispositivos point-of-care. La tecnología apunta a un mercado de diagnóstico de biomarcadores proyectado en 100.000 millones de dólares estadounidenses para 2030.
Micromem Technologies (OTCQB: MMTIF)는 초민감 질병 바이오마커 검출을 위해 설계된 혁신적인 액상형 나노와이어 생화학 센서를 공개했습니다. 이 센서는 1 피코몰 검출 한계와 20mV/데케이드 감도를 달성했으며, 염증의 핵심 지표인 TREM-1을 표적합니다.
이 플랫폼은 Department of National Defence를 위한 연구를 바탕으로 개발되었으며, 저비용 제조를 위해 표준 포토리소그래피를 사용합니다. 주요 특징으로는 pM 수준의 검출, 바이오마커 맞춤 표적화, 실시간 출력 및 현장진단(포인트오브케어) 장치와의 통합 가능성이 있습니다. 이 기술은 2030년까지 미화 1,000억 달러 규모로 예상되는 바이오마커 진단 시장을 겨냥하고 있습니다.
Micromem Technologies (OTCQB: MMTIF) a dévoilé un capteur biochimique révolutionnaire à nanofils en phase liquide, conçu pour la détection ultra-sensible de biomarqueurs de maladie. Le capteur atteint une limite de détection de 1 picomolaire et une sensibilité de 20 mV/décade, ciblant spécifiquement TREM-1, un marqueur inflammatoire clé.
La plateforme, développée à partir de travaux pour le Department of National Defence, utilise la photolithographie standard pour une fabrication rentable. Ses caractéristiques clés comprennent la détection au niveau pM, le ciblage personnalisable des biomarqueurs, une sortie en temps réel et la capacité d'intégration avec des dispositifs de point-of-care. La technologie vise un marché projeté de 100 milliards de dollars US pour la diagnostique des biomarqueurs d'ici 2030.
Micromem Technologies (OTCQB: MMTIF) hat einen bahnbrechenden flüssigphasigen Nanodraht-Biochemiesensor vorgestellt, der für die ultrasensitive Erkennung von Krankheits-Biomarkern entwickelt wurde. Der Sensor erreicht eine Nachweisgrenze von 1 Pikomolar und eine Empfindlichkeit von 20 mV/Dekade und richtet sich speziell gegen TREM-1, einen wichtigen Entzündungsmarker.
Die Plattform, entwickelt auf Basis von Arbeiten für das Department of National Defence, nutzt Standard-Photolithographie für eine kosteneffiziente Herstellung. Zu den Hauptmerkmalen gehören pM-Nachweis, anpassbare Biomarker-Zielausrichtung, Echtzeit-Ausgabe und Integrationsfähigkeit in Point-of-Care-Geräte. Die Technologie adressiert einen prognostizierten Markt von 100 Milliarden US-Dollar für Biomarker-Diagnostik bis 2030.
- Achieved ultra-sensitive 1 picomolar detection limit, enabling earlier disease detection
- Platform targets $100 billion USD biomarker diagnostics market by 2030
- Cost-effective manufacturing using standard photolithography processes
- Versatile application potential across multiple diseases and conditions
- Still requires field validation before commercial deployment
- Needs strategic partnerships for market penetration
- Early stage of commercialization with no immediate revenue impact
Toronto, Ontario and New York, New York--(Newsfile Corp. - August 11, 2025) - Micromem Technologies Inc. (CSE: MRM) (OTCQB: MMTIF) ("Micromem" or the "Company") is pleased to announce the successful development of its liquid-phase nanowire bio-chemical sensor, engineered to detect disease-associated biomarkers at ultra-low concentrations. This innovation marks a critical milestone in the pursuit of more accurate, earlier medical diagnostics.
The sensor has demonstrated limit-of-detection performance down to 1 picomolar (pM) and 20mV/decade sensitivity, enabling the identification of inflammatory and pathological biomarkers previously undetectable by conventional methods. The sensor platform is fabricated using standard photolithography processes, making it both cost-effective and scalable for high-volume industrial applications.
The initial target analyte is TREM-1 (Triggering Receptor Expressed on Myeloid Cells 1), a key marker known to amplify inflammatory responses and closely associated with a range of diseases including atherosclerosis, cancer, colitis, and fibrosis.
Platform Highlights:
- Ultra-Low Detection Thresholds: Achieves pM-level detection, suitable for early-stage disease monitoring.
- Broad Diagnostic Utility: Customizable for other critical biomarkers involved in cancer, autoimmune disease, and systemic inflammation.
- High Signal Clarity: Nanowire-based response delivers real-time, low-noise output with a strong correlation to analyte concentration.
- Compact and Integratable: Ready for deployment in next-generation lab-on-a-chip, point-of-care, or remote diagnostic devices.
- Manufactured via conventional photolithography techniques, the platform supports efficient, low-cost production-critical for widespread adoption in clinical and point-of-care diagnostics.
Market Relevance
With global demand for biomarker diagnostics expected to exceed
This liquid-phase sensor platform originated from work developed on behalf of the Department of National Defence and is evolving into a commercial diagnostic tool.
Micromem is positioning its gas detection technology for integration into industrial and environmental systems through targeted partnerships and pilot initiatives.
Precision medicine starts with precision detection. The Company's platform offers the sensitivity, flexibility, and scalability to support a wide array of clinical applications.
With the platform now ready for field validation, the Company is seeking co-development and deployment opportunities with strategic industry partners. Micromem is focused on expanding commercial readiness and welcomes pilot deployment opportunities.
About Micromem
Micromem Technologies Inc. and its subsidiaries, a publicly traded company (CSE: MRM) (OTCQB: MMTIF),develops, and commercializes advanced sensor solutions using proprietary nanotechnology and analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. It creates platforms the serve the needs of industries that demand accuracy, durability, and real-time intelligence in detection systems. By leveraging its expertise and experience with sophisticated sensor applications, the Company successfully powers the development and implementation of innovative solutions for oil & gas, utilities, automotive, healthcare, government, information technology, manufacturing and other industries. Visit www.micromeminc.com.
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; continued consumer adoption of digital technology; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer and technological demands; inability to replace significant customers; seasonal nature of our business; and other risks detailed in our filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The CSE or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
###
Listing: OTCQB - Symbol: MMTIF
CSE - Symbol: MRM
Shares issued: 607,024,014
SEC File No: 0-26005
Investor Contact: info@micromeminc.com; Tel. 416-364-2023 Subscribe to receive News Releases by Email on our website's home page. www.micromeminc.com.
¹ According to Grand View Research, the global biomarkers market was valued at USD 59.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262026
FAQ
What is the detection capability of Micromem's (MMTIF) new biosensor?
Which specific biomarker does MMTIF's new sensor target?
What is the market potential for Micromem's biosensor technology?
How is Micromem's (MMTIF) biosensor manufactured?
What are the potential applications for MMTIF's new sensor platform?
